Cipla Gains First AB-Rated gVentolin Approval in U.S. Respiratory Generics Market

Cipla's AB-rated generic albuterol sulfate inhalation aerosol approval marks the first time any manufacturer has cleared the FDA's therapeutic equivalence threshold for a pressurised metered-dose inhaler referencing Ventolin HFA, a regulatory and manufacturing milestone that resets the competitive baseline for U.S. respiratory generics.

Securing an AB rating for a pMDI generic requires demonstrating not only bioequivalence but formulation, device, and sterility assurance parity with the reference listed drug. The FDA's complex drug product pathway for orally inhaled and nasal drug products demands particle size distribution data, in vitro aerodynamic performance testing, and human pharmacokinetic studies, a package that has blocked multiple applicants for years. Cipla's clearance signals that its Indore or Goa manufacturing infrastructure, depending on the filing site, met the agency's current process validation expectations under 21 CFR Part 211.

The approval lands within a broader FY26 performance that saw Cipla record consolidated annual revenue of Rs. 28,163 crore, the highest in the company's history. Growth was distributed across India, Africa, and emerging markets businesses, reducing the headline risk of over-reliance on any single geography. For QA and regulatory leads tracking Cipla's U.S. trajectory, the gVentolin clearance is the more operationally significant data point: it confirms the site's readiness to supply a high-scrutiny dosage form into a market where FDA inspection outcomes directly gate commercial launch.

For plant heads managing inhaler manufacturing lines, the precedent is instructive. AB-rated pMDI generics require sustained post-approval commitments around propellant handling, valve component qualification, and container closure integrity, all areas where ICH Q10 pharmaceutical quality system principles apply with particular force. Any manufacturer evaluating a similar ANDA strategy should expect the agency to apply the same evidentiary standard Cipla has now met.

Cipla's ability to convert this approval into durable U.S. market share will depend on commercial launch timing, supply continuity from the approved site, and whether any subsequent AB-rated entrants compress the exclusivity window before volume commitments are secured.

Source: Media4Growth via Indian Pharma Post, 14 May 2026.